Recent advances and future directions in the management of metastatic renal cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Metastatic renal cell carcinoma (mRCC) treatment has been revolutionized by advances in molecular biology and the development of tyrosine kinase inhibitors (TKIs).
• Several TKIs, including multikinase inhibitors (sunitinib, sorafenib) and mTOR inhibitors (temsirolimus, everolimus), have demonstrated superiority over older treatments like interferon-alpha (IFN-alpha) or placebo.
• Combination therapies, such as bevacizumab with IFN-alpha, have also shown improved activity in mRCC patients.

Purpose of the Study:

• To review the current evidence supporting the use of TKIs in managing mRCC.
• To discuss the evolving landscape of TKI-based therapies, including monotherapy, combination with immunotherapy, and sequential or combined TKI approaches.
• To explore potential future directions in mRCC treatment strategies.

Main Methods:

• Literature review of clinical studies and trials investigating TKIs in mRCC.
• Analysis of data on TKI efficacy, toxicity, and combination strategies.
• Synthesis of evidence regarding monotherapy, sequential, and combined TKI approaches, as well as combinations with immunotherapy.

Main Results:

• TKIs have become a cornerstone in mRCC treatment, offering improved outcomes compared to historical therapies.
• Combination of TKIs with immunotherapy has yielded mixed results, with bevacizumab + IFN-alpha being a notable exception with positive outcomes.
• Investigational anti-vascular endothelial growth factor (VEGF) agents like axitinib, pazopanib, and cediranib are being explored for future treatment options.

Conclusions:

• TKIs represent a significant advancement in mRCC management, offering various therapeutic options.
• While synergistic TKI combinations aim to block multiple pathways, they often increase toxicity.
• Sequential TKI administration shows potential, but optimal sequencing requires further determination. Future research should focus on refining combination and sequential strategies to improve efficacy and manage toxicity in mRCC.